Recent developments in the treatment of acute abdominal and facial attacks of hereditary angioedema: focus on human C1 esterase inhibitor.

It was stopped before completion for ethical reasons because there was a strong and highly significant positive difference for rC1-INH versus placebo in median time to beginning of relief (62 versus 508 min, P = 0.0009) as well as time to minimal symptoms (480 versus 1480 min, P = 0.0038).

also in 132,142 other papers

The investigators of the FAST-1 suggest that this study did not reach statistical significance due to the stringent definition of the primary endpoint as well as the early use of rescue medication.

also in 111,027 other papers